Clinical trials: Waldenstroms Macroglobulinaemia
Hematologic Malignancies, Waldenstroms Macroglobulinaemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's…
- Conditions
- Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
- Trial name
- NCT04728893
- Testing
- Nemtabrutinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 490 people
- Sponsor
- Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD).
- Conditions
- Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease
- Trial name
- NCT07766421
- Testing
- Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate
- Volunteers
- 219 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL)
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL), Waldenstrom Macroglobulinaemia, Lymphoplasmacytic Lymphoma
- Trial name
- HEMO-CONNECT (NCT07592481)
- Testing
- Connected home blood pressure monitoring with daily IPA supervision.
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier de la côte Basque
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Waldenstrom Macroglobulinaemia, Multiple Myeloma
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
- Trial name
- BLOOD-dose (NCT07474961)
- Testing
- teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib)
- Where
- 5 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Anne Louise Tølbøll Sørensen
Waldenstrom Macroglobulinaemia, Peripheral Neuropathies
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs.
- Trial name
- NCT07160270
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Waldenstrom's Macroglobulinaemia Refractory
Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia.
- Trial name
- NCT06200220
- Testing
- Venetoclax
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Poitiers University Hospital
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Waldenstrom's Macroglobulinaemia
Randomised Trial in Waldenstrom's Macroglobulinaemia
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.
- Trial name
- R2W (NCT01592981)
- Testing
- Bortezomib, Cyclophosphamide, Rituximab
- Where
- 30 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B, Lymphoma, Small Lymphocytic
- Trial name
- NCT02991638
- Testing
- Ibrutinib
- Where
- Hong Kong
- Volunteers
- 62 people
- Sponsor
- The University of Hong Kong
Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed.
- Conditions
- Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinaemia
- Trial name
- NCT01805375
- Testing
- DI-B4
- Where
- 5 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Cancer Research UK
Waldenstrom Macroglobulinaemia
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of…
- Trial name
- NCT00811733
- Testing
- Ofatumumab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Symptomatic Waldenstroms Macroglobulinaemia
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and their production of monoclonal IgM…
- Trial name
- NCT01142011
- Testing
- Belimumab
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Cancer Trials Australia